Provided by Tiger Trade Technology Pte. Ltd.

Immix Biopharma, Inc.

13.66
+0.50003.80%
Post-market: 13.60-0.0600-0.44%19:30 EDT
Volume:1.51M
Turnover:20.41M
Market Cap:972.46M
PE:-15.76
High:13.76
Open:13.36
Low:13.12
Close:13.16
52wk High:13.76
52wk Low:1.94
Shares:71.19M
Float Shares:58.79M
Volume Ratio:1.00
T/O Rate:2.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8667
EPS(LYR):-0.8930
ROE:-34.18%
ROA:-20.52%
PB:4.25
PE(LYR):-15.30

Loading ...

Immix Biopharma Price Target Cut to $19.00/Share from $20.00 by Morgan Stanley

Dow Jones
·
Aug 12

Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating

MT Newswires Live
·
Aug 11

Immix Biopharma Publishes Corporate Presentation on NXC-201 BCMA CAR-T in Relapsed/refractory AL Amyloidosis

Reuters
·
Aug 11

Immix Biopharma is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 10

Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)

TIPRANKS
·
Aug 10

Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $25 from $20

THOMSON REUTERS
·
Aug 10

Immix Biopharma, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 08

Immix Biopharma Q2 FY26 Net Loss Widens to USD 11.56 Million; G&A Expense More than Doubled to USD 7.12 Million

Reuters
·
Aug 08

Immix Biopharma, Inc. Expected to Post a Loss of 18 Cents a Share - Earnings Preview

Reuters
·
Aug 05

Immix Biopharma to Attend Morgan Stanley Global Healthcare Conference, Host Investor Meetings

Reuters
·
Aug 04

Immix Biopharma Initiated at Buy by Needham

Dow Jones
·
Jul 22

Needham Initiates Immix Biopharma at Buy With $21 Price Target

MT Newswires Live
·
Jul 22

Immix Biopharma Inc : Needham Initiates Coverage with Buy Rating; Target Price $21

THOMSON REUTERS
·
Jul 22

Immix Biopharma Terminates Richard Graydon Employment

Reuters
·
Jul 20

Immix Biopharma - Richard Graydon Terminated from Immix Biopharma as of July 17, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 20

Immix Biopharma Posts Corporate Presentation Highlighting Nxc-201 CAR-T in Relapsed/refractory AL Amyloidosis

Reuters
·
Jul 03

Immix Biopharma Inc : Bofa Global Research Initiates Coverage With Buy Rating; Price Objective $27

THOMSON REUTERS
·
Jun 18

BofA Initiates Immix Biopharma at Buy With $27 Price Target

MT Newswires Live
·
Jun 18

Immix Biopharma Initiated at Outperform by LifeSci Capital

Dow Jones
·
Jun 18

Immix Biopharma publishes corporate presentation highlighting NXC-201 CAR-T in relapsed/refractory AL amyloidosis

Reuters
·
Jun 18